From Clinical Promise to Commercial Reality: Enabling Cell Therapy Commercialization at Scale
- Commercializing cell and gene therapies (CGTs) requires overcoming CMC bottlenecks, scaling complex autologous processes, and ensuring consistent batch performance from late-stage development through commercial supply.
- Minaris supports this transition with proven end‑to‑end manufacturing, regulatory readiness, and global tech transfer expertise—demonstrated through approved therapies like AMTAGVI® and commercial partnerships such as LYFGENIA®, achieving >95% success rates with a “Right First Time” philosophy.
- Outlining practical strategies for process validation, comparability, supply reliability, and scalable cell therapy manufacturing to enable sustainable commercialization and broader global patient access